Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for SRPT

Stock NameSarepta Therapeutics Inc
TickerSRPT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS8036071004
LEI549300IKDPIED8J8IG21

Show aggregate SRPT holdings

News associated with SRPT

Leerink Partners Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target raised by analysts at Leerink Partners from $12.00 to $15.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “market perform” rating on the biotechnology company’s stock. Leerink Partners’ price target would indicate a potential downside of 12.89% from the stock’s […] - 2025-09-11 03:04:49
After Hours Most Active for Aug 29, 2025 : ELAN, NVDA, GOOG, PPBI, SRPT, COLB, MSFT, SNAP, KMI, XOM, NEE, PFE
The NASDAQ 100 After Hours Indicator is down -7.17 to 23,408.25. The total After hours volume is currently 173,977,891 shares traded.The following are the most active stocks for the after hours session: Elanco Animal Health Incorporated (ELAN) is unchanged at $18.35, with 22,912 - 2025-08-29 17:29:12
HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. A number of other research firms have also issued reports on SRPT. Barclays raised shares of Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and […] - 2025-08-27 02:30:45
SCHK's Underlying Holdings Could Mean 11% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-21 10:39:22
Sarepta Therapeutics (NASDAQ:SRPT) Given New $17.00 Price Target at Bank of America
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective lifted by Bank of America to $17.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have an underperform rating on the biotechnology company’s stock. Other equities analysts have also issued reports about the company. Baird R W lowered Sarepta Therapeutics from […] - 2025-08-21 04:58:48
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $12.00
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective hoisted by Deutsche Bank Aktiengesellschaft to $12.00 in a research note released on Friday,Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a sell rating on the biotechnology company’s stock. Other research analysts have also issued reports about the stock. TD Cowen lowered shares of Sarepta Therapeutics […] - 2025-08-18 03:06:45
Vanguard Group Inc. Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Vanguard Group Inc. lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 9,032,613 shares of the biotechnology company’s stock after selling 52,843 shares during the quarter. Vanguard Group Inc. owned about 0.09% […] - 2025-08-14 04:37:10
Stocks Rally on Positive Tariff News ad Rate Cut Hopes
The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 18:57:35
Stocks Rally on Positive Tariff News ad Rate Cut Hopes
The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 13:11:34
Stocks Rally on Positive Tariff News ad Rate Cut Hopes
The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 12:48:17
Stocks Rally on Positive Tariff News ad Rate Cut Hopes
The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 12:41:53
Barclays Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to “Equal Weight”
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by analysts at Barclays from an “underweight” rating to an “equal weight” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The firm currently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price objective indicates a potential upside […] - 2025-07-31 05:26:59
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Barclays
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by research analysts at Barclays from an “underweight” rating to an “equal weight” rating in a report released on Tuesday, MarketBeat Ratings reports. The brokerage presently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price target would indicate a potential upside of 35.38% […] - 2025-07-31 05:26:59
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Equal Weight at Barclays
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by stock analysts at Barclays from an “underweight” rating to an “equal weight” rating in a research note issued on Tuesday, Marketbeat reports. The brokerage presently has a $22.00 price target on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 31.34% […] - 2025-07-31 05:26:59
BMO Capital Markets Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target hoisted by BMO Capital Markets from $25.00 to $50.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “market perform” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 198.51% from the stock’s […] - 2025-07-31 05:26:58
William Blair Reaffirms “Outperform” Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a research report issued on Tuesday,RTT News reports. Other equities analysts have also recently issued reports about the stock. Bank of America reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on […] - 2025-07-31 05:26:58
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective hoisted by equities researchers at Morgan Stanley from $15.00 to $20.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target suggests a potential upside of 19.40% from the stock’s […] - 2025-07-31 03:02:52
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating restated by analysts at HC Wainwright in a note issued to investors on Tuesday, MarketBeat.com reports. A number of other equities research analysts also recently commented on SRPT. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $32.00 to $18.00 […] - 2025-07-31 03:02:51
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by JPMorgan Chase & Co.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by equities researchers at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage currently has a $24.00 target price on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target […] - 2025-07-31 03:02:51
Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting
The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 12:49:47
Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting
The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 08:23:02
Sarepta Therapeutics (NASDAQ:SRPT) Earns “Underperform” Rating from Needham & Company LLC
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “underperform” rating reaffirmed by Needham & Company LLC in a report issued on Monday,Benzinga reports. Several other equities analysts have also recently issued reports on SRPT. Scotiabank raised Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price […] - 2025-07-30 04:54:53
Barclays Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to Strong Sell
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by equities research analysts at Barclays from a “hold” rating to a “strong sell” rating in a report released on Monday, MarketBeat Ratings reports. Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta […] - 2025-07-30 04:54:51
Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting
The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 03:41:41
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up Following Analyst Upgrade
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) shares gapped up before the market opened on Tuesday after Barclays upgraded the stock from an underweight rating to an equal weight rating. The stock had previously closed at $13.86, but opened at $18.23. Barclays now has a $22.00 price target on the stock. Sarepta Therapeutics shares […] - 2025-07-30 02:14:47
Strong Earnings and Trade Deal Optimism Bolster Stocks
The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.56%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures... - 2025-07-29 20:49:20
Stocks Slide in Afternoon Session
The S&P 500 Index ($SPX ) (SPY ) today is down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.25%. After starting off the day stronger, the 3 major stock indxes are in the... - 2025-07-29 20:19:00
Stocks Supported by Strong Earnings and Trade Deal Optimism
The S&P 500 Index ($SPX ) (SPY ) today is up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.25%. September E-mini S&P futures (ESU25 ) are up +0.03%, and September E-mini Nasdaq futures... - 2025-07-29 14:38:53
Stocks Supported by Strong Earnings and Trade Deal Optimism
The S&P 500 Index ($SPX ) (SPY ) today is up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.25%. September E-mini S&P futures (ESU25 ) are up +0.03%, and September E-mini Nasdaq futures... - 2025-07-29 14:12:43
Strong Earnings and Trade Deal Optimism Bolster Stocks
The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.56%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures... - 2025-07-29 14:12:42

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc SRPT holdings

DateNumber of SRPT Shares HeldBase Market Value of SRPT SharesLocal Market Value of SRPT SharesChange in SRPT Shares HeldChange in SRPT Base ValueCurrent Price per SRPT Share HeldPrevious Price per SRPT Share Held
2025-09-26 (Friday)35,013USD 642,839USD 642,839
2025-09-25 (Thursday)35,013USD 620,430SRPT holding decreased by -18907USD 620,4300USD -18,907 USD 17.72 USD 18.26
2025-09-24 (Wednesday)35,013USD 639,337USD 639,337
2025-09-17 (Wednesday)34,785USD 593,084SRPT holding decreased by -36525USD 593,0840USD -36,525 USD 17.05 USD 18.1
2025-09-16 (Tuesday)34,785USD 629,609USD 629,609
2025-09-12 (Friday)34,557USD 600,946USD 600,946
2025-09-11 (Thursday)34,557SRPT holding increased by 452USD 618,916SRPT holding increased by 18668USD 618,916452USD 18,668 USD 17.91 USD 17.6
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SRPT by Blackrock for IE00B3VWM098

Show aggregate share trades of SRPT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-11BUY452 17.910* 72.65
2025-08-21SELL-113 20.060* 72.96 Profit of 8,244 on sale
2025-07-31BUY339 16.420* 73.61
2025-07-28SELL-113 13.860* 74.68 Profit of 8,439 on sale
2025-06-30SELL-226 17.100* 81.39 Profit of 18,395 on sale
2025-06-25SELL-113 17.460* 82.74 Profit of 9,350 on sale
2025-06-20SELL-226 20.080* 84.10 Profit of 19,006 on sale
2025-05-23BUY113 37.900* 92.28
2025-05-19SELL-113 37.940* 94.11 Profit of 10,635 on sale
2025-05-15SELL-339 35.270* 95.13 Profit of 32,250 on sale
2025-05-12SELL-113 36.370* 96.73 Profit of 10,930 on sale
2025-05-09SELL-113 36.270* 97.28 Profit of 10,992 on sale
2025-04-30SELL-113 62.400* 100.27 Profit of 11,331 on sale
2025-04-24SELL-226 61.760* 101.86 Profit of 23,019 on sale
2025-04-22BUY1,478 59.310* 102.73
2025-04-17SELL-109 53.790* 104.28 Profit of 11,366 on sale
2025-04-15SELL-327 54.420* 105.37 Profit of 34,455 on sale
2025-04-14SELL-327 54.630* 105.92 Profit of 34,637 on sale
2025-04-09SELL-436 55.650* 107.75 Profit of 46,980 on sale
2025-04-07SELL-763 52.400* 109.07 Profit of 83,224 on sale
2025-04-04SELL-1,090 54.430* 109.72 Profit of 119,592 on sale
2025-03-31BUY109 63.820* 111.44
2025-03-19SELL-218 79.970* 115.48 Profit of 25,174 on sale
2025-03-14SELL-654 97.190* 116.52 Profit of 76,206 on sale
2025-03-13SELL-218 98.370* 116.78 Profit of 25,459 on sale
2025-03-12SELL-3,706 99.770* 117.03 Profit of 433,710 on sale
2025-03-07SELL-218 103.030* 117.75 Profit of 25,670 on sale
2025-03-06SELL-327 105.560* 117.94 Profit of 38,566 on sale
2025-03-03SELL-109 101.220* 118.62 Profit of 12,929 on sale
2025-02-28SELL-654 106.750* 118.81 Profit of 77,703 on sale
2025-02-26SELL-109 106.860* 119.28 Profit of 13,002 on sale
2025-02-25SELL-327 106.950* 119.49 Profit of 39,075 on sale
2025-02-18BUY545 105.350* 120.72
2025-02-13BUY109 109.460* 121.45
2025-02-12BUY109 109.810* 121.69
2025-02-11BUY327 109.680* 121.94
2025-02-06BUY981 112.110* 122.59
2025-01-27BUY109 116.890* 124.09
2024-12-30BUY545 121.190* 124.56
2024-12-06BUY436 128.170* 124.22
2024-12-05BUY109 126.280* 124.15
2024-12-04BUY545 126.530* 124.07
2024-11-29BUY545 133.340* 123.46
2024-11-27BUY436 137.940* 122.21
2024-11-26BUY109 130.500* 121.83
2024-11-21BUY545 110.500* 123.20
2024-11-20BUY327 110.860* 123.89
2024-11-18BUY1,308 104.670* 126.17
2024-11-12BUY872 114.320* 126.96
2024-11-08BUY545 121.610* 127.34
2024-11-07BUY1,620 120.420* 127.87
2024-11-06BUY216 127.970* 127.87
2024-10-31BUY108 126.000* 129.63
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SRPT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19983,56911,5822,229,35644.1%
2025-09-181,090,47513,2562,892,18137.7%
2025-09-171,084,43212,6462,880,08537.7%
2025-09-16894,02124,7942,572,51634.8%
2025-09-15965,39017,4131,966,97649.1%
2025-09-12653,9584,4501,496,52443.7%
2025-09-111,072,91220,7792,821,71038.0%
2025-09-101,151,23526,9382,519,73145.7%
2025-09-09912,3845,7001,971,30846.3%
2025-09-081,691,08614,2363,124,45754.1%
2025-09-05983,68832,9292,352,17841.8%
2025-09-04914,1254,0941,995,50145.8%
2025-09-031,510,13728,0813,442,47743.9%
2025-09-021,295,4201,7422,645,87349.0%
2025-08-291,216,3688,5982,467,99249.3%
2025-08-281,059,0254,6452,463,62643.0%
2025-08-271,514,6362132,902,51252.2%
2025-08-261,565,99849,8953,527,43544.4%
2025-08-252,838,9585,2296,270,84045.3%
2025-08-221,981,78231,8414,688,70342.3%
2025-08-214,086,13090,9177,046,33158.0%
2025-08-201,278,7054,5102,928,74143.7%
2025-08-19876,3141,4942,229,42439.3%
2025-08-181,204,4303,0102,779,04043.3%
2025-08-151,705,8679,1864,100,04041.6%
2025-08-141,349,4418353,381,57939.9%
2025-08-131,545,26520,7605,282,33129.3%
2025-08-121,305,8382,5073,231,12540.4%
2025-08-112,168,6739,1525,077,98542.7%
2025-08-082,133,50314,9324,694,28445.4%
2025-08-073,771,97442,4797,573,97949.8%
2025-08-062,783,5034,4765,375,05551.8%
2025-08-051,594,8466763,432,44546.5%
2025-08-044,127,0573,7787,480,14955.2%
2025-08-012,097,7514,0354,221,31849.7%
2025-07-313,263,53232,1437,100,48946.0%
2025-07-308,885,53612,37218,507,33748.0%
2025-07-2917,694,15467,60830,461,99558.1%
2025-07-284,761,652590,3969,578,71049.7%
2025-07-252,445,819120,8785,876,92241.6%
2025-07-249,985,202652,75020,571,46348.5%
2025-07-231,525,8395,3074,030,26637.9%
2025-07-224,478,481383,13310,024,47644.7%
2025-07-213,426,18878,3209,225,50637.1%
2025-07-1811,983,277545,93629,286,07140.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.